Spots Global Cancer Trial Database for rapamycin
Every month we try and update this database with for rapamycin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer | NCT02048384 | Metastatic Panc... | metformin alone... metformin (Arm ... rapamycin (Arm ... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | NCT06239480 | Microcystic Lym... | QTORIN 3.9% Rap... Placebo | 6 Years - | Palvella Therapeutics, Inc. | |
| Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis | NCT03500367 | Uterine Fibroid... | rapamycin | 18 Years - 50 Years | Peking Union Medical College Hospital | |
| Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies | NCT00449280 | Advanced Solid ... | Sorafenib Rapamycin Rapamycin | 18 Years - | University of Chicago | |
| Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | NCT00780104 | Myeloid Leukemi... AML Leukemia CML | Rapamycin, Mito... Rapamycin + MEC | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | NCT06239480 | Microcystic Lym... | QTORIN 3.9% Rap... Placebo | 6 Years - | Palvella Therapeutics, Inc. | |
| Aging Mammary Stem Cells and Breast Cancer Prevention | NCT02642094 | Cancer of Breas... | Rapamycin | 18 Years - 80 Years | The University of Texas Health Science Center at San Antonio | |
| Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma | NCT01684449 | Advanced Soft T... | Gemcitabine + R... | 18 Years - 70 Years | Grupo Espanol de Investigacion en Sarcomas | |
| Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy | NCT01827618 | Invasive Bladde... | Rapamycin | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Sirolimus in Treating Patients With Glioblastoma Multiforme | NCT00047073 | Brain and Centr... | Rapamycin Surgery Supportive Care | 18 Years - 120 Years | Jonsson Comprehensive Cancer Center | |
| A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer | NCT02753309 | Bladder Cancer | Sirolimus | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Individualized Drug Treatment for Treating Patients With Pancreatic Cancer | NCT00276744 | Pancreatic Canc... | cetuximab capecitabine docetaxel Erlotinib Gemcitabine Irinotecan mitomycin C rapamycin conventional su... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma | NCT03436732 | Mesothelioma | LMB-100 SEL-110 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Topical Rapamycin to Erase Angiofibromas in TSC | NCT01526356 | Angiofibromas Tuberous Sclero... | Placebo Rapamycin Rapamycin | - | The University of Texas Health Science Center, Houston | |
| Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis | NCT03140449 | Facial Angiofib... | Rapamycin Calcitriol Rapamycin-calci... | 7 Years - 65 Years | National Taiwan University Hospital | |
| Individualized Drug Treatment for Treating Patients With Pancreatic Cancer | NCT00276744 | Pancreatic Canc... | cetuximab capecitabine docetaxel Erlotinib Gemcitabine Irinotecan mitomycin C rapamycin conventional su... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas | NCT01412892 | Neurofibromatos... Plexiform Neuro... Neurofibromatos... | RAD001: Everoli... | 18 Years - 60 Years | Assistance Publique - Hôpitaux de Paris | |
| Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations | NCT03243019 | Lymphatic Malfo... Pediatric | rapamycin MRI Rapamycin dosag... | - 18 Years | University Hospital, Lille | |
| Aging Mammary Stem Cells and Breast Cancer Prevention | NCT02642094 | Cancer of Breas... | Rapamycin | 18 Years - 80 Years | The University of Texas Health Science Center at San Antonio | |
| Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM | NCT00490789 | Tuberous Sclero... Lymphangioleiom... | sirolimus | 18 Years - 65 Years | Cardiff University | |
| Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine | NCT01396200 | Myeloma | Hydroxychloroqu... Rapamycin | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | NCT00780104 | Myeloid Leukemi... AML Leukemia CML | Rapamycin, Mito... Rapamycin + MEC | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | NCT06239480 | Microcystic Lym... | QTORIN 3.9% Rap... Placebo | 6 Years - | Palvella Therapeutics, Inc. | |
| Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis | NCT03500367 | Uterine Fibroid... | rapamycin | 18 Years - 50 Years | Peking Union Medical College Hospital | |
| Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies | NCT00449280 | Advanced Solid ... | Sorafenib Rapamycin Rapamycin | 18 Years - | University of Chicago | |
| Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation | NCT03767660 | Blue Rubber Ble... Venous Malforma... | Rapamycin | - | Peking Union Medical College Hospital | |
| Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM | NCT00490789 | Tuberous Sclero... Lymphangioleiom... | sirolimus | 18 Years - 65 Years | Cardiff University | |
| Docetaxel and Sirolimus in Patients With Advanced Malignancies | NCT01054313 | Advanced Cancer | Docetaxel (Taxo... Sirolimus (Rapa... Prednisone | - | M.D. Anderson Cancer Center | |
| Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway | NCT04736589 | Breast Cancer | Inetetamab Rapamycin Pyrotinib Chemotherapy | 18 Years - 85 Years | Peking Union Medical College | |
| Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma | NCT02596828 | Pineoblastoma | Temozolomide Irinotecan Dasatinib Rapamycin | 0 Years - 25 Years | University of Regensburg | |
| Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) | NCT01184898 | AML | Sirolimus Mitoxantrone Etoposide Cytarabine | 18 Years - | Thomas Jefferson University | |
| RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS | NCT00126672 | Nonmalignant Ne... Tuberous Sclero... Lymphangioleimy... Kidney Angiomyo... | Rapamycin | 3 Years - 65 Years | Dana-Farber Cancer Institute | |
| Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma | NCT02596828 | Pineoblastoma | Temozolomide Irinotecan Dasatinib Rapamycin | 0 Years - 25 Years | University of Regensburg | |
| Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients | NCT00235560 | Acute Myeloid L... | rapamycin | 60 Years - | University Hospital, Toulouse | |
| A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer | NCT00411788 | Breast Cancer | Rapamycin Trastuzumab | 18 Years - | Yale University | |
| Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex | NCT05534672 | Tuberous Sclero... | Rapamycin Placebo | 3 Months - 50 Years | Children's Memorial Health Institute, Poland | |
| Study of Rapamycin Plus Ketoconazole in Advanced Cancers | NCT00708591 | Advanced Cancer | Rapamycin Ketoconazole | 18 Years - | University of Chicago | |
| Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma | NCT01467986 | Neuroblastoma R... | Dasatinib Rapamycin Irinotecan Temozolomide Irinotecan Temozolomide | - 25 Years | University of Regensburg | |
| RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS | NCT00126672 | Nonmalignant Ne... Tuberous Sclero... Lymphangioleimy... Kidney Angiomyo... | Rapamycin | 3 Years - 65 Years | Dana-Farber Cancer Institute | |
| Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer | NCT00409994 | Rectum Cancer | Rapamycin | - | Maastricht Radiation Oncology | |
| Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex | NCT03826628 | Facial Angiofib... Tuberous Sclero... | rapamycin placebo | 6 Years - 65 Years | Dermatology Specialties Limited Partnership | |
| Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy | NCT03578432 | Salivary Gland ... Xerostomia Head and Neck C... | Everolimus Laboratory Biom... Survey Administ... | 18 Years - 75 Years | University of Arizona | |
| Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy | NCT00402415 | Tumors | Sunitinib malat... Rapamycin | 18 Years - | Yale University | |
| Docetaxel and Sirolimus in Patients With Advanced Malignancies | NCT01054313 | Advanced Cancer | Docetaxel (Taxo... Sirolimus (Rapa... Prednisone | - | M.D. Anderson Cancer Center | |
| Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | NCT00473551 | Leukemia Lymphoma Myeloma | Rituximab Cyclophosphamid... Fludarabine Mesna Radiation Treat... Stem Cell Trans... Sirolimus Anti-third Part... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Sirolimus for Cowden Syndrome With Colon Polyposis | NCT04094675 | PTEN Gene Mutat... PTEN Hamartoma ... PTEN Hamartoma ... Cowden Syndrome Bannayan Syndro... Bannayan Zonana... Polyposis | Sirolimus | 18 Years - 80 Years | Ohio State University | |
| Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | NCT00780104 | Myeloid Leukemi... AML Leukemia CML | Rapamycin, Mito... Rapamycin + MEC | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis | NCT03140449 | Facial Angiofib... | Rapamycin Calcitriol Rapamycin-calci... | 7 Years - 65 Years | National Taiwan University Hospital | |
| Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas | NCT01412892 | Neurofibromatos... Plexiform Neuro... Neurofibromatos... | RAD001: Everoli... | 18 Years - 60 Years | Assistance Publique - Hôpitaux de Paris | |
| Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | NCT00780104 | Myeloid Leukemi... AML Leukemia CML | Rapamycin, Mito... Rapamycin + MEC | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma | NCT01467986 | Neuroblastoma R... | Dasatinib Rapamycin Irinotecan Temozolomide Irinotecan Temozolomide | - 25 Years | University of Regensburg | |
| Sirolimus for Cowden Syndrome With Colon Polyposis | NCT04094675 | PTEN Gene Mutat... PTEN Hamartoma ... PTEN Hamartoma ... Cowden Syndrome Bannayan Syndro... Bannayan Zonana... Polyposis | Sirolimus | 18 Years - 80 Years | Ohio State University | |
| Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma | NCT01684449 | Advanced Soft T... | Gemcitabine + R... | 18 Years - 70 Years | Grupo Espanol de Investigacion en Sarcomas | |
| Rapamycin in Relapsed Acute Lymphoblastic Leukemia | NCT00874562 | Acute Lymphobla... | Corticosteroid Rapamycin | 365 Days - | Dana-Farber Cancer Institute | |
| Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma | NCT04448873 | Kaposiform Hema... Kasabach-Merrit... | Sirolimus | - 12 Years | Children's Hospital of Fudan University | |
| A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT00861874 | Acute Myeloid L... | Decitabine Rapamycin | 18 Years - | University of Rochester | |
| Topical Rapamycin for Fibrofolliculomas | NCT00928798 | Birt-Hogg-Dubé ... | Rapamycin placebo | 18 Years - | Maastricht University Medical Center | |
| Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis | NCT06308445 | Familial Adenom... | Rapamycin | 12 Years - 17 Years | University Hospital, Toulouse | |
| Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway | NCT04736589 | Breast Cancer | Inetetamab Rapamycin Pyrotinib Chemotherapy | 18 Years - 85 Years | Peking Union Medical College | |
| Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00467194 | Liver Cancer | Rapamycin Bevacizumab | 18 Years - | National Cancer Centre, Singapore | |
| Rapamycin in Relapsed Acute Lymphoblastic Leukemia | NCT00874562 | Acute Lymphobla... | Corticosteroid Rapamycin | 365 Days - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
